Background: Case reports and small short case series have described patients with sarcoidosis and melanoma. Objectives: To examine the relation between sarcoidosis and melanoma. Methods: Computerized search of all patients seen at our department of dermatology between 1998 and 2007 and review of the literature using a Medline search from 1985 to June 2008. Results: We identified 7 cases in our population of 1,199 melanoma inpatients. Including these cases, 20 cases of sarcoidosis have been described in melanoma patients. Fifteen patients had their sarcoidosis diagnosed after melanoma. In 7 cases, sarcoidosis was related to immunotherapy. Sarcoidosis presented mainly as pulmonary disease without severe organ involvement, with a benign evolution. Conclusion: Our referral center study shows a prevalence of sarcoidosis of 0.58% among melanoma inpatients. Clinicians should be aware of the possibility that sarcoidosis may initially manifest itself in melanoma patients, especially after treatment with immunotherapy, and mimic metastatic disease.

Keywords:
Ipilimumab, Interferon α, Malignant melanoma, Sarcoidosis
1.
Brincker H, Wilbek E: The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974;29:247–251.
2.
Brincker H: Coexistence of sarcoidosis and malignant disease: causality or coincidence? Sarcoidosis 1989;6:31–43.
3.
Romer FK, Hommelgaard P, Schou G: Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 1998;12:906–912.
4.
Brincker H: The sarcoidosis-lymphoma syndrome. Br J Cancer 1986;54:467–473.
5.
Rayson D, Burch PA, Richardson RL: Sarcoidosis and testicular carcinoma. Cancer 1998;83:337–343.
6.
Paparel P, Devonec M, Perrin P, Ruffion A, Decaussin-Petrucci M, Akin O, Sheinfeld J, Guillonneau B: Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall. Sarcoidosis Vasc Diffuse Lung Dis 2007;24:95–101.
7.
Suen JS, Forse MS, Hyland RH, Chan CK: The malignancy-sarcoidosis syndrome. Chest 1990;98:1300–1302.
8.
Brincker H: Solid tumors preceding or following sarcoidosis. Med Pediatr Oncol 1987;15:82–88.
9.
Cohen PR, Kurzrock R: Sarcoidosis and malignancy. Clin Dermatol 2007;25:326–333.
10.
Rubinstein I, Baum GL, Yellin A, Herczeg E: Sarcoidosis: a cause of bilateral hilar lymphadenopathy after excision of malignant melanoma of the arm. South Med J 1985;78:1139–1140.
11.
Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A: Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999;160:1668–1672.
12.
Seersholm N, Vestbo J, Viskum K: Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax 1997;52:892–894.
13.
Baughman RP, Lower EE, du Bois RM: Sarcoidosis. Lancet 2003;361:1111–1118.
14.
Brincker H: Sarcoid reactions in malignant tumours. Cancer Treat Rev 1986;13:147–156.
15.
Shigemitsu H: Is sarcoidosis frequent in patients with cancer? Curr Opin Pulm Med 2008;14:478–480.
16.
Mackenzie H, Retsas S: Malignant melanoma co-existing with sarcoidosis: implications for prognosis and management. Melanoma Res 1996;6:71–72.
17.
Robert C, Schoenlaub P, Avril MF, Lok C, Grosshans E, Valeyre D, Bourgeois C, Pinquier L, Dubertret L, Guillaume JC: Malignant melanoma and granulomatosis. Br J Dermatol 1997;137:787–792.
18.
Haluska P, Luetmer PH, Inwards CY, Afessa B, Shives TC, Ingle JN: Complications of therapy and a diagnostic dilemma case. Case 3. Diagnostic dilemma: sarcoidosis simulating metastatic malignancy. J Clin Oncol 2003;21:4653–4654.
19.
Toulemonde A, Quereux G, Dreno B: Sarcoidosis granuloma on a tattoo induced by interferon alpha (in French). Ann Dermatol Venereol 2004;131:49–51.
20.
Echigo T, Saito A, Takehara K, Takata M, Hatta N: Coexistence of micrometastatic melanoma cells and sarcoid granulomas in all regional lymph nodes in a patient with acral melanoma. Clin Exp Dermatol 2003;28:375–376.
21.
Hendrickx BW, van Herpen CM, Bonenkamp JJ, Bulten J, Oyen WJ: Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. Case 1: mediastinal sarcoidosis in a melanoma patient treated with interferon. J Clin Oncol 2005;23:8906–8907.
22.
Alonso-Perez A, Ballestero-Diez M, Fraga J, Garcia-Diez A, Fernandez-Herrera J: Cutaneous sarcoidosis by interferon therapy in a patient with melanoma. J Eur Acad Dermatol Venereol 2006;20:1328–1329.
23.
Mahood JM: Malignant melanoma arising from a congenital pigmented naevus in a patient with sarcoidosis: cause or coincidence? Clin Exp Dermatol 2006;31:665–667.
24.
Pelletier F, Manzoni P, Jacoulet P, Humbert P, Aubin F: Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma. Cutis 2007;80:441–445.
25.
Massaguer S, Sanchez M, Castel T: Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma. Eur Radiol 2004;14:1716–1717.
26.
Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouma L, Thomas L: Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009;218:69–70.
27.
Gherardi GJ: Localized lymph node sarcoidosis associated with carcinoma of the bile ducts: report of a case. AMA Arch Pathol 1950;49:163–168.
28.
Pavic M, Debourdeau P, Vacelet V, Rousset H: Sarcoidosis and sarcoid reactions in cancer (in French). Rev Med Interne 2008;29:39–45.
29.
Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W, Hemminki K, Linet MS, Goldin LR: Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321–1330.
30.
Mellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, Hemminki K, Olsen JH, Dreyer L, Linet MS, Goldin LR, Landgren O: Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin’s lymphoma. Arthritis Rheum 2008;58:657–666.
31.
Kurata A, Terado Y, Schulz A, Fujioka Y, Franke FE: Inflammatory cells in the formation of tumor-related sarcoid reactions. Hum Pathol 2005;36:546–554.
32.
Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007;357:2153–2165.
33.
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC: Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234–241.
34.
Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, Sato N, Endo K: FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003;32:133–138.
35.
Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ: Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987;59:896–900.
36.
Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, Cervera R, Font J: Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69–80.
37.
Parronchi P, Mohapatra S, Sampognaro S, Giannarini L, Wahn U, Chong P, Mohapatra S, Maggi E, Renz H, Romagnani S: Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996;26:697–703.
38.
Cranmer LD, Hersh E: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007;25:613–631.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.